Phase IB Dose Escalation and Expansion Study of AKT Inhibitor Afuresertib with Carboplatin and Paclitaxel in Recurrent Platinum-resistant Ovarian CancerSarah P. Blagden, Hani Gabra, Jeffrey C. Goh et al.|Clinical Cancer Research|2018Cited by 66
3 Afuresertib (GSK2110183), an oral AKT kinase inhibitor, in combination with carboplatin and paclitaxel in recurrent ovarian cancerSarah P. Blagden, Hani Gabra, Anne Hamilton et al.|European Journal of Cancer|2014Cited by 8
Phase I/II dose-escalation and expansion study of afuresertib + carboplatin and paclitaxel in recurrent ovarian cancer.Sarah P. Blagden, Tarek Meniawy, Hani Gabra et al.|Journal of Clinical Oncology|2016Cited by 4